ETFs Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-02-06 pm EST			5-day change	1st Jan Change
89.02 ^USD	-0.36%		-3.19%	+8.74%

Feb. 05	Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage	MT
Feb. 05	Vaxcyte, Inc. Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for Prevention of Invasive Pneumococcal Disease in Infants	CI

ETFs positioned on Vaxcyte, Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.27%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.1%	0 M€	0.00%	-
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0.01%	9 M€	+3.87%	-
ARMOR US EQUITY INDEX ETF - USD	0.01%	0 M€	-.--%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0.01%	21 M€	+1.82%	-

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

2025-03-02 - Q4 2024 Earnings Release (Projected)

More about the company